268 related articles for article (PubMed ID: 22651119)
1. On the independence of data monitoring committee in adaptive design clinical trials.
Chow SC; Corey R; Lin M
J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
[TBL] [Abstract][Full Text] [Related]
2. Issues in data monitoring and interim analysis of trials.
Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
[TBL] [Abstract][Full Text] [Related]
3. Issues in regulatory guidelines for data monitoring committees.
DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
[TBL] [Abstract][Full Text] [Related]
4. Playing safe and preserving integrity: making the FDA model work.
Wittes J
Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731
[TBL] [Abstract][Full Text] [Related]
5. Futility approaches to interim monitoring by data monitoring committees.
Demets DL
Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
[TBL] [Abstract][Full Text] [Related]
6. Data monitoring committees, interim analysis and early termination in paediatric trials.
Fernandes RM; van der Lee JH; Offringa M
Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
[TBL] [Abstract][Full Text] [Related]
7. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
Bryant J
Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
Tijssen JG
Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
[TBL] [Abstract][Full Text] [Related]
9. The independent statistician for data monitoring committees.
DeMets DL; Fleming TR
Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
[TBL] [Abstract][Full Text] [Related]
10. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
11. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
Lilienfeld DE
Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
[TBL] [Abstract][Full Text] [Related]
13. Current controversies in data monitoring for clinical trials.
Pocock SJ
Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
[TBL] [Abstract][Full Text] [Related]
14. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
Ellenberg SS; George SL
Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
[TBL] [Abstract][Full Text] [Related]
15. Ethical issues during the conduct of clinical trials.
Silverman H
Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
[TBL] [Abstract][Full Text] [Related]
16. Liability issues for data monitoring committee members.
DeMets DL; Fleming TR; Rockhold F; Massie B; Merchant T; Meisel A; Mishkin B; Wittes J; Stump D; Califf R
Clin Trials; 2004; 1(6):525-31. PubMed ID: 16279293
[TBL] [Abstract][Full Text] [Related]
17. Strength of accumulating evidence and data monitoring committee decision making.
George SL; Freidlin B; Korn EL
Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
[TBL] [Abstract][Full Text] [Related]
18. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
Chuang-Stein C; Beltangady M
J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
[TBL] [Abstract][Full Text] [Related]
19. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
[TBL] [Abstract][Full Text] [Related]
20. Regulatory perspectives on data monitoring.
O'Neill RT
Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
